Table_2_Resveratrol Derivatives as Potential Treatments for Alzheimer’s and Parkinson’s Disease.DOCX (24.26 kB)

Table_2_Resveratrol Derivatives as Potential Treatments for Alzheimer’s and Parkinson’s Disease.DOCX

Download (24.26 kB)
dataset
posted on 17.04.2020 by Bruno Dutra Arbo, Corinne André-Miral, Raif Gregorio Nasre-Nasser, Lúcia Emanueli Schimith, Michele Goulart Santos, Dennis Costa-Silva, Ana Luiza Muccillo-Baisch, Mariana Appel Hort

Neurodegenerative diseases are characterized by the progressive loss of neurons in different regions of the nervous system. Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most prevalent neurodegenerative diseases, and the symptoms associated with these pathologies are closely related to the regions that are most affected by the process of neurodegeneration. Despite their high prevalence, currently, there is no cure or disease-modifying drugs for the treatment of these conditions. In the last decades, due to the need for the development of new treatments for neurodegenerative diseases, several authors have investigated the neuroprotective actions of naturally occurring molecules, such as resveratrol. Resveratrol is a stilbene found in several plants, including grapes, blueberries, raspberries, and peanuts. Studies have shown that resveratrol presents neuroprotective actions in experimental models of AD and PD, however, its clinical application is limited due to its rapid metabolism and low bioavailability. In this context, studies have proposed that structural changes in the resveratrol molecule, including glycosylation, alkylation, halogenation, hydroxylation, methylation, and prenylation could lead to the development of derivatives with enhanced bioavailability and pharmacological activity. Therefore, this review article aims to discuss how resveratrol derivatives could represent viable molecules in the search for new drugs for the treatment of AD and PD.

History

References

Licence

Exports